ClinicalTrials.gg
RecruitingNCT07305922DecibelUpdated Dec 26, 2025

Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension

An observational study in Subarachnoid Aneurysm Hemorrhage and Cerebral Vasospasm After Subarachnoid Hemorrhage, sponsored by Region Stockholm. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Region Stockholm · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Subarachnoid Hemorrhage with a site in Sweden — 3 open to participants now, 4 under way, none of them phase 3. Subarachnoid Hemorrhage · Sweden.

Started
2025
with 1 other
Observational
4 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Region Stockholm

Among the 10 studies in Subarachnoid Hemorrhage with a site in Sweden, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 10th registered.

Subarachnoid Hemorrhage

513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.

Browse Subarachnoid Hemorrhage studies →

Open to participants now

3 of the 10 studies in Subarachnoid Hemorrhage with a site in Sweden are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Subarachnoid Hemorrhage with a site in Sweden, or all of them as a file.
02

Study summary

An observational study of patients with emerging or established severe cerebral vasospasm after subarachnoid haemorrhage, employing multimodal neuromonitoring.

03

Conditions studied

  • Subarachnoid Aneurysm Hemorrhage
  • Cerebral Vasospasm After Subarachnoid Hemorrhage

Keywords

  • Transcranial Doppler
  • Endoluminal Spasmolysis
  • Induced Hypertension
  • Multimodal Neuromonitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated for subarachnoid haemorrhage at the Intensive care unit at Karolinska University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years or older
  • Critical care after subarachnoid haemorrhage
  • Aneurysm secured by surgical clipping or endovascular procedure
  • Suspected, emerging or established severe cerebral vasospasm

Exclusion criteria

Exclusion Criteria:

  • Anticipated survival less than five days, as determined by treating clinician
  • Transcranial Doppler signal too weak
  • Pregnancy
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with emerging or established severe cerebral vasospasm after subarachnoid haemorrhage

    Drug: Induced hypertension with norepinephrine · Drug: Endoluminal Spasmolysis

Interventions

  • DrugInduced hypertension with norepinephrine

    Induced hypertension with norepinephrine and/or dobutamine to attain clinically established goals of cerebral perfusion pressure in a stepwise fashion, according to clinical routine.

  • DrugEndoluminal Spasmolysis

    Endoluminal spasmolysis of cerebral arteries using i.a. Nimodipine, according to clinical protocol and neurointerventionist discretion.

06

What researchers measure

Primary outcomes

  1. Mean Flow Velocity (MFV)

    Increase or decrease of Mean Flow Velocity of the medial cerebral artery as determined by Transcranial Doppler.

    Time frame: Up to 12 hours post intervention

Secondary outcomes

  1. Duration of MFV change after Endoluminal Spasmolysis

    Time until Mean Flow Velocity, as determined by Transcranial Doppler, returns to or surpasses baseline.

    Time frame: Up to 12 hours

Other outcomes

  1. Associations between Mean Flow Velocity and multimodal neurophysiologic measurement variables after endoluminal spasmolysis or induced hypertension.

    Associations between Mean Flow Velocities, as determined by Transcranial Doppler, and other neurophysiologic measurement variables, such as pbtO2 (partial pressure brain tissue oxygenation), SbtO2 (brain tissue saturation), qEEG (quantitative EEG), microdialysis parameters, Prx (pressure reactivity index), as well as other physiologic output parameters such as cardiac output, (as determined by left ventricular output or effective pulmonary blood flow (EPBF)).

    Time frame: Up to 12 hours

  2. Associations between Mean Flow Velocity and neuroradiological outcome after induced hypertension or endoluminal spasmolysis.

    Associations between Mean Flow Velocity, as determined by Transcranial Doppler, and neuroradiologic outcome parameters such as cerebral artery diameter, perfusion parameters, mean transit time (MTT), ischemic burden.

    Time frame: Up to 12 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Observational, hypothesis-generating study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2029, 48 months after the start.

Of 117 non-industry observational studies under Subarachnoid Hemorrhage, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 127. This study's planned 48 months is above that.

Counting every sponsor, half of 120 studies reached it within 40 months; a quarter within 19 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Dec 26, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07305922
Lead sponsor
Region Stockholm
Responsible party
Peter Rudberg (Senior Consultant, Research Group Leader, Karolinska Institutet) — Principal investigator
First posted
Dec 26, 2025
Start date
Dec 1, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Dec 26, 2025

Study contacts

Peter C Rudberg, M.D. Ph.D.
Contact
peter.rudberg@ki.se
+46-8-12370000 ext. 72341
Anja Rosén, M.D.
Contact
anja.rosen@ki.se
+46-8-12370000 ext. 94856

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion